Retatrutide, an experimental weight-loss medication currently under development by Eli Lilly, has become the subject of widespread counterfeit production despite never receiving regulatory approval for human use. The drug remains in Phase III clinical trials, and only 50% of drugs at this testing stage in the United States receive eventual FDA approval. Nevertheless, illicit versions of retatrutide are being sold across the UK through informal channels including gyms, salons, social media platforms, and street vendors.
Health professionals have expressed significant concern about the proliferation of fake versions. Endocrinologist Prof Donal O’Shea reports that young patients are presenting to hospitals with serious adverse effects including nausea, vomiting, diarrhea, and kidney failure. Some personal trainers are reportedly administering counterfeit injections to clients without clear communication about dosage or contents. Pharmacist Sehar Shahid notes that people are “injecting an illegal drug and thinking it’s safe,” with open discussion of suppliers occurring on social media platforms.
Eli Lilly has warned that illicit retatrutide products may contain unknown ingredients, harmful contaminants, impurities, incorrect dosages, or entirely wrong ingredients. Dr Nas Khattak, a research doctor screening participants for Eli Lilly’s Phase III trial, notes that those obtaining counterfeit versions are essentially acting as unmonitored test subjects. Clinical trial participants undergo strict medical evaluations including GP record reviews, mental health assessments, and blood work before participation.
Retatrutide’s appeal stems from its mechanism as a potential “triple G” medication—the first weight-loss drug to target three hormone receptors: GLP-1, GIP, and glucagon. This contrasts with currently approved obesity medications like semaglutide and tirzepatide, which target one or two receptors. Users report experiencing reduced appetite and significant weight loss, though documented cases include overdoses and severe side effects requiring near-hospitalization.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI